3 stories
AI briefings + tags; source links are the ground truth.
About
🇩🇰
Denmark
Politiken
National & Local
Novo-chef: We are affected by two factors pulling in the wrong direction
Novo Nordisk anticipates a 5 to 13 percent decline in sales by 2026 due to two specific negative factors despite expecting continued demand for its medicines, as explained by CEO Mike Doustdar during a teleconference following the 2025 financial report.
Feb 4 • 08:49 UTC
🇩🇰
Denmark
Politiken
National & Local
Novo-chef: We are affected by two factors that pull in the wrong direction
Novo Nordisk anticipates a revenue decline of 5 to 13 percent in 2026 due to two specific factors, despite not expecting a drop in demand for its medications.
Feb 4 • 08:49 UTC
🇩🇰
Denmark
Politiken
National & Local
Dismal prediction: If Novo is right, 2026 could become the company's worst year in this millennium
Novo Nordisk is facing a potential downturn as sales growth from weight loss drugs slowed, despite surpassing expectations with Wegovy sales reaching 21.9 billion kroner in the fourth quarter of 2025.
Feb 3 • 17:17 UTC